EMI56, the derivative of EMI1, displays greater potency toward mutant EGFR than EMI1. EMI56 inhibits EGFR triple mutants[1].

EMI56 inhibits EGFR ex19del/T790M/C797S and EGFR L858R/T790M/C797S. EMI56 can be used in the research of mutant EGFR-associated, drug-resistant non-small-cell lung cancer (NSCLC)[1].EMI56 (10, 15, 20 μM; 2 h of treatment) strongly inhibits total EGFR levels, activation and downstream signaling in PC9 EGFR ex19del/T790M/C797S cells[1].

2414374-41-5

C21H20N2O3

348.4

EMI56

DMSO:50 mg/mL (143.51 mM),ultrasonic and warming and heat to 60°C
Powder: -20°C for 3 years
In solvent: -80°C for 2 years